https://www.selleckchem.com/btk.html
The progression-free survival (PFS) of first-line combination of atezolizumab with platinum-based chemotherapy and sequential second-line treatment with BRAFi Vemurafenib are 20 and 5.5 months, respectively. This case shows a durable response to ICPi in V600E non-smoking lung adenocarcinoma with PFS of 20 months under first-line atezolizumab plus chemotherapy treatment. The case supports the idea that the combination immunotherapy may be an attractive option for V600E mutated non-smoking NSCLC with high PD-L1 expression. This case shows a durable re
Like
Comment
Share
